PDF(Pubmed)
Abstract：
UNASSIGNED: A significant number of individuals diagnosed with non-small cell lung cancer (NSCLC) have distant metastases, and the concept of oligometastatic NSCLC has shown promise in achieving a cure. Stereotactic body radiation therapy (SBRT) is currently considered a viable treatment option for a limited number of tumor metastases. It has also been demonstrated that third-generation tyrosine kinase inhibitors (TKIs) are effective in extending the survival of patients with epidermal growth factor receptor (EGFR)-mutated NSCLC. Hence, the combination of SBRT with third-generation TKIs holds the potential to enhance treatment efficacy in patients with oligometastatic EGFR-mutated NSCLC. This review aimed to assess the possibility of combining SBRT with TKIs as an optimum treatment option for patients with oligometastatic EGFR-mutated NSCLC.
UNASSIGNED: We performed a narrative review by searching the PubMed, Web of Science, Elsevier and ClinicalTrials.gov databases for articles published in the English language from January 2009 to February 2024 and by reviewing the bibliographies of key references to identify important literature related to combining SBRT with third-generation TKIs in oligometastatic EGFR-mutated NSCLC.
UNASSIGNED: This review aimed to assess the viability of combining SBRT and EGFR-TKIs in oligometastatic EGFR-mutated NSCLC. Current clinical trials suggest that the combined therapies have better progression free survival (PFS) when using SBRT as either concurrent with EGFR-TKIs or consolidated with EGFR-TKIs. Furthermore, research with third-generation EGFR-TKIs and SBRT combinations has demonstrated tolerable toxicity levels without significant additional adverse effects as compared to prior therapies. However, further clinical trials are required to establish its effectiveness.
UNASSIGNED: The combined approach of SBRT and TKIs can effectively impede the progression of oligometastatic NSCLC in patients harboring EGFR mutations and, most notably, can prolong progression-free survival rates. However, the feasibility of combining SBRT with third-generation TKIs in clinical trials remains unclear.
UNASSIGNED: We performed a narrative review by searching the PubMed, Web of Science, Elsevier and ClinicalTrials.gov databases for articles published in the English language from January 2009 to February 2024 and by reviewing the bibliographies of key references to identify important literature related to combining SBRT with third-generation TKIs in oligometastatic EGFR-mutated NSCLC.
UNASSIGNED: This review aimed to assess the viability of combining SBRT and EGFR-TKIs in oligometastatic EGFR-mutated NSCLC. Current clinical trials suggest that the combined therapies have better progression free survival (PFS) when using SBRT as either concurrent with EGFR-TKIs or consolidated with EGFR-TKIs. Furthermore, research with third-generation EGFR-TKIs and SBRT combinations has demonstrated tolerable toxicity levels without significant additional adverse effects as compared to prior therapies. However, further clinical trials are required to establish its effectiveness.
UNASSIGNED: The combined approach of SBRT and TKIs can effectively impede the progression of oligometastatic NSCLC in patients harboring EGFR mutations and, most notably, can prolong progression-free survival rates. However, the feasibility of combining SBRT with third-generation TKIs in clinical trials remains unclear.
摘要：
■大量诊断为非小细胞肺癌（NSCLC）的个体有远处转移，寡转移非小细胞肺癌的概念在实现治愈方面显示出了希望。立体定向身体放射疗法（SBRT）目前被认为是有限数量的肿瘤转移的可行治疗选择。已经证明第三代酪氨酸激酶抑制剂(TKIs)可有效延长表皮生长因子受体(EGFR)突变的NSCLC患者的生存期。因此，SBRT与第三代TKIs的组合具有增强寡转移EGFR突变NSCLC患者治疗疗效的潜力.这篇综述旨在评估SBRT与TKIs联合作为寡转移EGFR突变NSCLC患者最佳治疗选择的可能性。
■我们通过搜索PubMed进行了叙述性审查，WebofScience,Elsevier和ClinicalTrials.gov数据库收集了2009年1月至2024年2月以英语发表的文章，并回顾了关键参考文献的参考书目，以确定与将SBRT与第三代TKIs结合在寡转移EGFR突变的NSCLC中的重要文献。
■这篇综述旨在评估SBRT和EGFR-TKIs联合治疗寡转移EGFR突变的非小细胞肺癌的可行性。目前的临床试验表明，当使用SBRT与EGFR-TKIs同时或与EGFR-TKIs合并时，联合疗法具有更好的无进展生存期（PFS）。此外，第三代EGFR-TKIs和SBRT联合治疗的研究表明,与之前的治疗相比,毒性水平可耐受,且无明显的额外不良反应.然而,需要进一步的临床试验来确定其有效性。
■SBRT和TKIs的联合方法可以有效阻止EGFR突变患者的寡转移NSCLC的进展，最值得注意的是,可以延长无进展生存率。然而,在临床试验中结合使用SBRT和第三代TKIs的可行性尚不清楚.
■我们通过搜索PubMed进行了叙述性审查，WebofScience,Elsevier和ClinicalTrials.gov数据库收集了2009年1月至2024年2月以英语发表的文章，并回顾了关键参考文献的参考书目，以确定与将SBRT与第三代TKIs结合在寡转移EGFR突变的NSCLC中的重要文献。
■这篇综述旨在评估SBRT和EGFR-TKIs联合治疗寡转移EGFR突变的非小细胞肺癌的可行性。目前的临床试验表明，当使用SBRT与EGFR-TKIs同时或与EGFR-TKIs合并时，联合疗法具有更好的无进展生存期（PFS）。此外，第三代EGFR-TKIs和SBRT联合治疗的研究表明,与之前的治疗相比,毒性水平可耐受,且无明显的额外不良反应.然而,需要进一步的临床试验来确定其有效性。
■SBRT和TKIs的联合方法可以有效阻止EGFR突变患者的寡转移NSCLC的进展，最值得注意的是,可以延长无进展生存率。然而,在临床试验中结合使用SBRT和第三代TKIs的可行性尚不清楚.
